Circassia Pharmaceuticals Plc Notification of Major Interest in Shares (3813C)

TIDMCIR TIDMAZN

RNS Number : 3813C

Circassia Pharmaceuticals Plc

12 April 2017

 
 
 
 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 
-------------------------------------------------------------------------------------------------- 
 
 1. Identity of the issuer or                                     Circassia Pharmaceuticals 
  the underlying issuer                                            plc 
  of existing shares to which 
  voting rights are 
  attached: (ii) 
---------------------------------------------------------------  --------------------------------- 
 2 Reason for the notification (please tick the appropriate 
  box or boxes): 
-------------------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                                       X 
------------------------------------------------------------------  ------------------------------ 
 An acquisition or disposal of qualifying financial 
  instruments which may result in the acquisition 
  of shares already issued to which voting rights 
  are attached 
------------------------------------------------------------------  ------------------------------ 
 An acquisition or disposal of instruments with 
  similar economic effect to qualifying financial 
  instruments 
------------------------------------------------------------------  ------------------------------ 
 An event changing the breakdown of voting rights 
------------------------------------------------------------------  ------------------------------ 
 Other (please 
  specify): 
---------------------------------------------------------  -------  ------------------------------ 
 3. Full name of person(s)                                    AstraZeneca PLC 
  subject to the 
  notification obligation: 
  (iii) 
-----------------------------------------------------------  ------------------------------------- 
 4. Full name of shareholder(s)                               AstraZeneca UK Limited 
  (if different from 3.):(iv) 
-----------------------------------------------------------  ------------------------------------- 
 5. Date of the transaction                                   12 April 2017 
  and date on 
  which the threshold is 
  crossed or 
  reached: (v) 
-----------------------------------------------------------  ------------------------------------- 
 6. Date on which issuer                                      12 April 2017 
  notified: 
-----------------------------------------------------------  ------------------------------------- 
 7. Threshold(s) that is/are                                  3% through to 14% (inclusive) 
  crossed or 
  reached: (vi, vii) 
-----------------------------------------------------------  ------------------------------------- 
 
 
 
 8. Notified details: 
---------------------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares (viii, ix) 
---------------------------------------------------------------------------------------------------------------------- 
 Class/type     Situation previous                   Resulting situation after the 
  of             to the triggering                    triggering transaction 
  shares         transaction 
 
  if possible 
  using 
  the ISIN 
  CODE 
-------------  -----------------------------------  ------------------------------------------------------------------ 
                Number            Number             Number          Number of voting         % of voting 
                of                 of                 of shares       rights                   rights (x) 
                Shares             Voting 
                                   Rights 
-------------  ----------------  -----------------  --------------  -----------------------  ------------------------- 
                                                     Direct          Direct     Indirect      Direct        Indirect 
                                                                     (xi)        (xii) 
-------------      ------------    -------------    --------------  ---------  ------------  ------------  ----------- 
 Ordinary 
  shares of 
  0.08 pence    0                 0                  47,355,417      0          47,355,417    0             14.25% 
               ----------------  -----------------  --------------  ---------  ------------  ------------  ----------- 
 GB00BJVD3B28 
-------------      ------------    -------------      ------------    -------  ------------      --------    --------- 
 
 B: Qualifying Financial Instruments 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of            Expiration      Exercise/                          Number of voting           % of voting 
 financial           date            Conversion                         rights that                rights 
 instrument          (xiii)          Period (xiv)                       may be 
                                                                        acquired if 
                                                                        the 
                                                                        instrument 
                                                                        is 
                                                                        exercised/ 
                                                                        converted. 
-----------------  --------------  ---------------------------------  -------------------------  --------------------- 
 N/A 
-----------------  --------------  ---------------------------------  -------------------------  --------------------- 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments (xv, xvi) 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of          Exercise        Expiration       Exercise/         Number of voting           % of voting 
 financial         price          date             Conversion         rights instrument          rights (xix, 
 instrument                       (xvii)           period             refers to                  xx) 
                                                   (xviii) 
---------------  --------------  ---------------  ----------------  -------------------------  ----------------------- 
 N/A                                                                                            Nominal       Delta 
---------------  --------------  ---------------  ----------------  -------------------------  ------------  --------- 
 
 
 Total (A+B+C) 
---------------------------------------------------------------------------------------------------------------------- 
 Number of voting rights                               Percentage of voting rights 
----------------------------------------------------  ---------------------------------------------------------------- 
 47,355,417                                            14.25% 
----------------------------------------------------  ---------------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable: 
  (xxi) 
------------------------------------------------------------------------- 
 AstraZeneca PLC (parent Company) 
 
  AstraZeneca Intermediate Holdings Limited (wholly owned 
  subsidiary of AstraZeneca PLC) 
 
  AstraZeneca UK Limited (99.994% owned by AstraZeneca 
  Intermediate Holdings Limited and 0.006% owned by AstraZeneca 
  PLC) - holder of 47,355,417 Ordinary Shares in Circassia 
  Pharmaceuticals plc 
 
 Proxy Voting: 
------------------------------------------------------------------------- 
 10. Name of the proxy holder:                               N/A 
----------------------------------------------------------  ------------- 
 11. Number of voting rights proxy                           N/A 
  holder will cease 
  to hold: 
----------------------------------------------------------  ------------- 
 12. Date on which proxy holder will                         N/A 
  cease to hold 
  voting rights: 
----------------------------------------------------------  ------------- 
 
 
  13. Additional information: 
----------------------------------------------------------  ------------- 
 14. Contact name:                                           Julien Cotta 
----------------------------------------------------------  ------------- 
 15. Contact telephone number:                               01865 405560 
----------------------------------------------------------  ------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLITMFTMBTBBLR

(END) Dow Jones Newswires

April 12, 2017 12:34 ET (16:34 GMT)